Measurement-based care using DSM-5 for opioid use disorder:can we make opioid medication treatment more effective? by Marsden, John et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1111/add.14546
Document Version
Publisher's PDF, also known as Version of record
Link to publication record in King's Research Portal
Citation for published version (APA):
Marsden, J., Tai, B., Ali, R., Hu, L., Rush, A. J., & Volkow, N. (2019). Measurement-based care using DSM-5 for
opioid use disorder: can we make opioid medication treatment more effective? Addiction.
https://doi.org/10.1111/add.14546
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 05. Apr. 2019
Measurement-based care using DSM-5 for opioid use
disorder: can we make opioid medication treatment
more effective?
John Marsden1 , Betty Tai2, Robert Ali3, Lian Hu2,4, A. John Rush5,6,7 & Nora Volkow2
Addictions Department, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, UK,1 National Institute on Drug Abuse, National Institutes of Health,
Rockville, MD, USA,2 Discipline of Pharmacology, School of Medicine, The University of Adelaide, South Australia,3 The Emmes Corporation, Rockville, MD, USA,4
Duke-National University of Singapore, Singapore,5 Department of Psychiatry, Duke University Medical School, Durham, USA6 and Department of Psychiatry,
Texas Tech Health Sciences Center, TX, USA7
ABSTRACT
Context and Purpose Measurement-based care (MBC) is an evidence-based health-care practice in which indicators of
disease are tracked to inform clinical actions, provide feedback to patients and improve outcomes. The current opioid crisis
in multiple countries provides a pressing rationale for adopting a basic MBC approach for opioid use disorder (OUD) using
DSM-5 to increase treatment retention and effectiveness. Proposal To stimulate debate, we propose a basic MBC
approach using the 11 symptoms of OUD (DSM-5) to inform the delivery of medications for opioid use disorder (MOUD;
including methadone, buprenorphine and naltrexone) and their evaluation in ofﬁce-based primary care and specialist
clinics. Key features of a basic MBC approach for OUD using DSM-5 are described, with an illustration of how clinical
actions are guided and outcomes communicated. For core treatment tasks, we propose that craving and drug use response
to MOUD should be assessed after 2 weeks, and OUD remission status should be evaluated at 3, 6 and 12months (and exit
from MOUD treatment) and beyond. Each of the 11 DSM-5 symptoms of OUD should be discussed with the patient to
develop a case formulation and guide selection of adjunctive psychological interventions, supplemented with information
on substance use, and optionally extended with information from other clinical instruments. A patient-reported outcome
measure should be recorded and discussed at each remission assessment. Conclusions MBC can be used to tailor and
adapt MOUD treatment to increase engagement, retention and effectiveness. MBC practice principles can help promote
patient-centred care in OUD, personalized addiction therapeutics and facilitate communication of outcomes.
Keywords DSM-5, measurement-based care (MBC), medications for opioid use disorder (MOUD), opioid use disorder
(OUD), patient reported outcome (PRO), psychological intervention.
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PURPOSE AND BACKGROUND
In this Addiction Debate article, we describe the concept,
clinical procedures and probable beneﬁts of a simple
measurement-based care (MBC) approach for opioid use
disorder (OUD [1]). MBC can be applied to any treat-
ment in the substance use disorders ﬁeld, but we focus
on ﬁrst-line medications delivered in primary care and
specialist clinics. This is because the current opioid crisis
and dramatic increase in fatal opioid-related poisonings
in the United States, Canada, Australia and several other
countries in Europe [2–5] have led to an urgent call to
increase provision in primary care [6] and a national
initiative in the United States to increase the capacity
and integration of treatment in hospitals, state health
departments, specialist programmes and the criminal
justice system [7].
MBC is an evidence-based health-care practice in
which disease symptoms, signs or biomarkers are used to
inform clinical actions, with feedback given to patients
about their progress in treatment to increase engagement,
adherence and beneﬁcial exposure to evidence-based ther-
apies. Physical health conditions are almost always treated
like this (e.g. hypertension and diabetes, in which blood
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pressure and glycated haemoglobin, respectively, are pri-
mary biomarkers in clinical practice).
In mental health, many clinical decisions are guided by
the presence and severity of patient-reported symptoms.
For example, the nine-item version of the Patient Health
Questionnaire (PHQ-9) [8] was constructed from the
symptoms of major depressive disorder in DSM-IV. Follow-
ing pivotal randomized controlled trials of antidepressant
medications [9,10], the PHQ-9 has become the most
widely used measure for MBC in depression [11,12]. The
PHQ-9 total score informs the selection and switching
of medications, the patient’s response to psychological
therapy and provides a standard metric to communicate
outcomes.
Why do we need an MBC approach?
Pharmacotherapeutic and psychological approaches
for OUD are delivered in out-patient clinics and ofﬁces
and in-patient hospital settings and residential settings.
Ongoing prescriptions of medications for OUD [MOUD; oral
methadone (MET) and sublingual buprenorphine (BUP)]
are the ﬁrst-line treatments used in many countries
world-wide and are our focus here. Meta-analysis of ran-
domized controlled trials concludes that MET and BUP
are associated with the suppression of non-medical opioid
use and increased periods of abstinence [13,14]. Observa-
tional follow-up studies of treatment routinely delivered
show reductions in drug injecting [15,16], opioid overdose
[17], blood-borne viral infections [18] and crime [19].
Recent randomized controlled efﬁcacy trials have shown
clinical beneﬁt for extended-release injectable depot
formulations of naltrexone (an opioid antagonist) and
BUP [20–22].
Given these positive ﬁndings, why do we need MBC?
One compelling reason is that the average treatment effect
from MOUD research masks many patients’ actual experi-
ence. Up to 40–50% of patients discontinue MOUD treat-
ment, most within a month [23,24], and many follow a
repeating cycle of re-admission and early discontinuation
[25]. In an inﬂuential randomized controlled study of
MOUD for people with prescription medication OUD, Roger
Weiss and colleagues observed that more than a quarter of
their sample were unable to stop non-medical opioid use
after 2 weeks of BUP, with this early non-response strongly
predictive of drug use 3 months later in treatment [26]. In
England, among a national cohort of 12745 patients who
received 12–26weeks of MOUD, 64% used heroin on 10 of
the past 28 days at follow-up [27]. In a further study of
7719 patients who were continuously enrolled in MOUD
for 5 years, one-seventh made early gains, but then
relapsed after approximately 6 months, with a tendency
to use heroin on approximately half the days of the month
prior to every subsequent bi-annual review [28]. There has
been a sustained effort to improve MOUD outcomes, with
study of adjunctive psychological interventions the most
common research strategy. However, pooled results from
a Cochrane Review of 13 different interventions have been
interpreted to indicate weak evidence, with no one modal-
ity judged effective (relative risk for abstinence = 1.03; 95%
conﬁdence interval = 0.98–1.07) [29].
Much has been learned from long-standing efforts in
the alcohol and drug ﬁeld to develop clinical outcome
monitoring systems [30–32]. A patient’s response to treat-
ment will be inﬂuenced by several factors, including
their ability and motivation to adhere to their prescription
(e.g. distance travelled to receive dosing and clinical prac-
tice on directly observed or self-administered dosing and
attendance).
Another reason that MBC is needed is because repeated
calls for treatment services and systems to monitor out-
comes [33,34] has not led to widespread action. Several
relatively brief instruments are in routine use in health-
care systems, including the Brief Addiction Monitor devel-
oped for the US Veterans Administration [35] and the
Treatment Outcomes Proﬁle, the national outcome stan-
dard for drug and alcohol treatment services in England
for the past decade [36]. However, neither instrument
was designed to diagnose substance use disorder (SUD) or
classify remission. There is no consensus on which indica-
tors are most relevant for MBC and few services would
describe themselves as MBC-driven.
MBC using DSM-5 symptoms
The DSM-5 OUD checklist is usually completed solely for
administrative reasons (e.g. to seek insurance authoriza-
tion for treatment) or to document eligibility criteria for a
research study. Surprisingly, these questions are rarely used
in the clinic either as a means of planning treatment or
classifying remission. Many practitioners are attuned to
their patients’ signs and symptoms and respond when
OUD worsens or improves, but time pressures often mean
that treatment is not monitored closely.
We suggest that for OUD the logical starting point for
an MBC orientation designed to increase engagement and
response is to focus on the 11 symptoms of the disorder
in DSM-5. Although the APA system is used in themajority
of research reports, we acknowledge that some readers
work in treatment systems which diagnose opioid depen-
dence using the World Health Organization International
Classiﬁcation of Disease (WHO ICD) system. The proposals
in this article apply equally well to the latest release of the
ICD (WHO; ICD-11) [37]. It will be interesting to determine
whether ICD-11 has any advantages over DSM-5 for MBC.
DSM-5 OUD is widely used and known, but a brief
summary is warranted. OUD is a latent construct with
11 symptoms (each scored as met or not-met) which fall
2 John Marsden et al.
© 2019 The Authors. Addiction published by John Wiley & Sons Ltd on behalf of Society for the Study of Addiction. Addiction
on a single severity dimension [38]. Six items address phys-
iological and cognitive behavioural aspects causally related
to neurobiological and neurocognitive adaptations follow-
ing opioid exposure (i.e. tolerance; withdrawal symptoms;
using more than intended; problems controlling consump-
tion; time spent involved with opioids; and distressing crav-
ing). The remaining ﬁve items capture risk of harm and
harmful social consequences caused by opioid use and in-
toxication (i.e. physically hazardous use; using despite
health problems caused or exacerbated; failure to meet role
obligations; continued use despite social problems; activi-
ties reduced or given up). Conceptually, each symptom is
a response (either direct or indirect) of exposure to opioids
or is a harm that ismaintained orworsened by chronic use.
Scoring DSM-5 OUD is straightforward: a diagnosis is
met if at least two symptoms are experienced within
the same period in the past 12 months. OUD severity is
judged by the number of symptoms met: mild, 2–3; moder-
ate, 4–5; or severe, 6–11. The minimal score for severe
OUD may not include any negative consequences, but a
higher level of severitymust involve some health and/or so-
cial impairment. A person diagnosed with OUD is classiﬁed
as being in ‘early remission’ if no symptoms are met for at
least 3 months. The craving symptom is not counted, nor
an item referring to tolerance and withdrawal if the person
is enrolled in and fully compliant with MOUD.
Practical proposals for MBC
Establishing a clinical diagnosis will always be an essential
clinical task, but even minimal probing for additional infor-
mation for each endorsed item can provide valuable insight
for care planning, delivery and adaptation as treatment
progresses. Each symptom can be extensible with further
probing questions as needed, including administration of a
clinical instrument developed for treatment planning [39].
To the best of our knowledge, the DSM-5 OUD working
group selected a 3-month point for evaluation of early re-
mission because it has long been believed that this is the
point from which clinically meaningful outcomes are ob-
served [40]. We think this is sensible, but we also recom-
mend evaluation at 6 months from treatment initiation.
‘Stable remission’ is assigned to someone who has no
OUD symptoms for at least 12 months (not including crav-
ing and discounting tolerance and withdrawal, if enrolled
in and fully compliant with MOUD). A speciﬁer denotes
whether the person is living in a controlled medical or cus-
todial setting. For those patients retained in longer-term
treatment, it would seem reasonable to expect that a remis-
sion status evaluation is performed twice-yearly and at exit.
In the following sections, we describe a basic MBC ap-
proach using the example of MOUD delivered in primary
care and specialist clinics. In these services, we will assume
that patients are able to access adjunctive interventions
directly or by referral. Space limitations preclude discussion
of: populations with complex needs (e.g. severe mental
health; personality factors; neurocognitive impairment;
chronic medical conditions); transfer procedures to hospi-
tal in-patient or residential programmes; and system-level
factors which bear heavily on access and the delivery of
effective MOUD. By ‘basic’ we mean activities that do not
unduly compete with time for direct care and have a
minimal administrative burden on the patient. We do not
summarize medical management to increase adherence,
but note that this is an important partner procedure.
At treatment initiation and review, a focus on each
OUD symptom helps to structure discussion and helps the
clinician and patient to formulate a testable hypothesis
about why OUD has occurred, how biological, psychologi-
cal and social factors are linked to opioid use and harms
and the options available to capitalize or strengthen the
patient’s resources for recovery [41]. There is a logic in
targeting interventions on the ﬁrst 6 items of OUD to
address its negative consequences. In addition to needed
adjustments to MOUD dosing (i.e. to attenuate distressing
craving and achieve opioid blockade), early clinical tasks
should include education on risk reduction and/or either
a watchful waiting approach for improvements in social
functioning or making an early referral.
It can be expected that reducing and quitting use of
illicit opioids (and/or analgesic products containing opioids
not taken as directed or non-prescribed) will ameliorate
negative consequences but some social harmsmay endure,
or emerge either because other contributing factors were
not modiﬁed or were due to new causes. Although the
craving symptom is not used for remission diagnosis, we
think it is an important and actionable item for MBC,
because distressing craving experiences may trigger the
use of drugs and this symptom can persist long into absti-
nence. Optionally, and according to capacity, a patient
who describes distressing craving could be asked to com-
plete a single-item rating scale or a multi-dimensional
questionnaire (e.g. [42]). Even a brief discussion could help
to build therapeutic alliance, increase change motivation
and interest to engage with treatment.
A basic MBC framework is summarized in Table 1. The
third column shows examples of how each domain could
be optionally extended with additional questions. These
are examples, and there are numerous ways in which this
basic framework could be expanded. At a minimum, we
suggest that basic information on substance use should
be recorded. In OUD, opioid use (and the route of adminis-
tration and frequency) is an essential behavioural descrip-
tor and an indicator of health risk, so a minimal set of
questions should also be asked about recent illicit and
non-medical drug use.
Given the increased risk of fatal poisoning when
opioids are consumed with other central nervous system
3
© 2019 The Authors. Addiction published by John Wiley & Sons Ltd on behalf of Society for the Study of Addiction. Addiction
depressants, the patient should also be asked about recent
use of sedative medications and heavy alcohol consump-
tion [43]. Cocaine use could also be monitored, as this is
prevalent in some populationswith OUD and canmoderate
MOUD engagement and response [44]. Informed by the
research literature on differential response to treatment,
we suggest an early assessment of illicit and non-medical
opioid use after the ﬁrst 2 weeks of METor BUP prescribing.
For every patient retained after the onset of treatment,
DSM-5 OUD remission should then be assessed at the ﬁrst
Table 1 DSM-5 opioid use disorder (OUD) criteria and examples of extended questions.
Domain Class/type/criterion Example of questions
A. Substance use Opioids
Sedatives
Stimulants (e.g. cocaine)
Used in the past 3 months or 6 or 12 months? If
yes, frequency: every day; 5–6 times a week; 3–4
times a week; twice a week; once a week; 1–3
times a month; less often. Were drugs injected?
Heavy alcohol use USA: drank more than 4 (women) or 5 (man)
standard drinks on a single occasion of 2 hours or
less in the past 3 months (same response scale as
above for frequency)?
OUD criterion (not met/met) Examples of question topics if criterion met
B. Physiological 1. Usual dose of opioid has diminished effect, or
need to take higher dose for required effecta
Self-reported typical dose? use of other opioids?
motivation for seeking drug effect?
2. Experience of opioid withdrawal symptoms
(or use to avoid)c
Settings when experienced withdrawal symptoms;
drugs taken to avoid/manage
C. Cognitive and
behavioural control
3. Using opioids more often, or for longer than
intended
Typical settings for obtaining and using (places
and people). What were the thoughts and believes
that accompanied compromised intention?
4. Unsuccessful attempts to reduce or quit
opioids
Actions taken to avoid opioid use and reasons for
lack of success?b
5. Time spent obtaining, using, recovering
from opioids
Has time spent obtainingopioids caused problems?
Examples of negative experiences during and after
using?
6. Bothered/distressed by strong urge
(cravings) for opioidsc
Last time: strength of urge to use (0–10; not at all–
extremely). Situations, triggers, feelings,
intentions/plans, desistance experiences.
D. Health risks
and harms
7. Using opioids in physically hazardous
situations
Which hazardous situations (e.g. driving, using
machinery)?
8. Opioid use despite known psychological or
physical health problem caused or exacerbated
Which problems are affected? How does opioid use
make the problem worse? NB: any screening
indicated for comorbid conditions?
E. Negative social
consequences
9. Failure to meet major role obligations
because of opioids
Recent speciﬁc examples of how opioid impacted
on personal roles at home, work or in education?
Who has been affected? How often does this
happen?
10. Continued use of opioids despite social
problems
Specify current inter-personal (e.g. primary
relationship; family) or occupational conﬂicts
affected by opioid use. How often does this
happen?
11. Important activities reduced or given up
because of opioids
Which social, occupational, vocational,
recreational activities? What opportunities are
there to help restart?
aItem not met if patient enrolled in opioid substitution treatment and is abstaining from non-prescribed and/or illicit opioids. bCan also assess patient’s moti-
vation, capability/opportunity and personal resources to address. cItem not met if the patient enrolled in opioid substitution treatment and is taking medica-
tions for OUD (MOUD) medication as directed. A review of adequacy of ongoing prescription dose and/or dispensing arrangements indicated if the patient is
abstaining from all non-medical opioids (veriﬁed by urine drug screen) but reports opioid withdrawal symptoms. Scoring: Admission: past 12months severity
(items 4–14): 2–3 = mild; 4–5 = moderate; 6–11 = severe. After 3 months in MOUD: 3-month remission = no items met (item C6 not counted). After
6 months in MOUD: 6-month remission = no items met (item C6 not counted). After 12 months in MOUD: 1-year sustained remission = no items met (item
C6 not counted).
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clinic visit after 3, 6 and 12 months. For patients enrolled
in longer-term MOUD, a 6-month frequency of remission
status is also appropriate.
Given the causal logic underpinning DSM-5, if a patient
enrolled in MOUD is completely abstinent, then the crite-
rion for remission is met, even if a psychological interven-
tion is still indicated for distressing craving. Conversely,
while occasional opioid use does not have a direct bearing
on OUD status, monitoring change in consumption is valu-
able to the patient and clinician, and a biochemical mea-
sure (e.g. urine drug screen) may be helpful to verify
recent abstinence so that lapses can be discussed and inter-
ventions implemented.
A patient report outcome (PRO) will also help to iden-
tify the patient’s perspective and promote collaboration
with them when assessing remission status. With no inter-
pretation required from the clinician, this is a simple mea-
sure of the impact of treatment (or broader progress
themes) in terms of what is important to the patient. PRO
measures are being used increasingly for research in sev-
eral disease-speciﬁc areas. Comprehensive OUD-speciﬁc
measures have been developed which record personal
perceptions of progress towards recovery [45] and quality
of life [46].
If there are time pressures, a single global PRO for
change in OUD symptoms following a period of treatment
could be used instead (e.g. very much improved; much im-
proved; a little improved; no change; a little worse; much
worse; verymuchworse). Administering this PROmeasure
as part of the assessment of remission could be very infor-
mative, especially when a patient’s OUD status and their
own perception of change do not match. This measure
should not replace DSM-5monitoringas the primary focus,
but will be very informatively linked to it.
There are many combinations of OUD symptoms that
describe non-response. In cases where remission is not
attained, there are several key questions to be asked:
• Is there a change in the severity of OUD?
• Has OUD improved or has it worsened?
• what does change in OUD severity say about response to
preceding interventions?
• How should this inform opportunities to adjust the care
plan and add additional treatment?
Checking which symptoms are met in comparison with
intake assessment will help to update the case formulation
and could point to an alteration in the patient’s care plan.
For example, early continued use of illicit opioids might
prompt an increase in medication dose, a review of dosing
arrangements and a discussion of safety issues. One or
more heavy drinking days could prompt provision of
guided self-help information. The nature of each DSM-5
symptom met could also inform a speciﬁc psychological
intervention or referral to accessible medical, welfare and
social services in the local community and/or a peer
support group. Screening for depression (e.g. the two-item
version of the PHQ-9 [47] and the item on suicidality) and
physical health conditions [HIV, hepatitis C virus (HCV)] is
also indicated. Some people with OUDwill have co-existing
problems (e.g. with stimulant drugs) and also long-
standing social problems (e.g. housing instability;
unemployment; and family conﬂict).
These factors add complexity to treatment planning
and may risk discontinuation and poor outcome. The
opportunity to respond here will depend on time and
resources. Even if remission is elusive or is not achieved
for long, MOUD may provide some symptom control and
protection against opioid poisoning. The clinician should
also not be disheartened if a MOUD-resistant patient re-
fuses an adjunctive intervention, as they may accept this
offer in the future. If there is no response after continuous
treatment, cliniciansmight consider whether to shift to an-
other MOUDmedication, as they have different pharmaco-
logical properties that might be more suitable for some
patients than others. Another consideration is the timing
of treatment intervention during ongoing care (early ver-
sus later). More research is needed to address the current
absence of evidence on which patient characteristics pre-
dict response to one MOUD versus another.
MBC research
We hope that pragmatic randomized controlled trials will
be performed to evaluate the effectiveness of MBC for
MOUD and other OUD interventions. Our proposals for
MBC can guide end-point selection and analysis in clinical
trials (where DSM-5 remission status is not often used in
end-point evaluations). At the very least, a single-item
PRO measure could be helpfully included in treatment
trials as secondary outcome measures. Cohort research
on MBC delivery for OUD within health-care systems
would also provide additional insights on response to spe-
ciﬁc interventions received, generating valuable real-world
evidence for the system itself as well as for the wider OUD
treatment community.
CONCLUSIONS
The current opioid crisis in many countries provides a
pressing rationale for adopting an MBC approach to in-
crease treatment effectiveness for OUD. We need to act
quickly and effectively to address non-response to MOUD
in the face of unprecedented levels of treatment need. We
believe that implementingMBC practice principles will pro-
mote patient-centred care in the treatment of OUD with
MOUD primary and specialist care. MBC has the potential
to stimulate the development of personalized addiction
therapeutics and improve patient engagement and reten-
tion in all treatments for OUD so that health and social
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harms are reduced or prevented, as well as promoting a
common metric for communicating outcomes. It is essen-
tial for OUD remission status to be recorded, as a basic min-
imum, so that progress can be measured effectively and
consistently. MBC will not sit comfortably in the busy clinic
if health-care professionals see it as a burden that competes
with time spent with the patient; but as DSM-5 is recorded
already, all we are advocating is the discussion of these
symptoms with the patient as part of care planning, build-
ing and sustaining therapeutic engagement and adapting
treatment to clinical response. Using DSM-5 for MBC
should be the minimum standard for MOUD treatment.
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